LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
An2 Therapeutics Inc.
Headquarters:
Menlo park, CA, United States
Website:
http://www.an2therapeutics.com...
Year Founded:
2019
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Eric Easom, MBA
Number Of Employees:
22
Enterprise Value:
$-42,455,047
PE Ratio:
-0.72
Exchange/Ticker 1:
NASDAQ:ANTX
Exchange/Ticker 2:
N/A
Latest Market Cap:
$37,322,400
BioCentury
|
Nov 21, 2024
Management Tracks
Boshoff to succeed Dolsten as Pfizer CSO
Plus: Hwang joins Metaphore, Flagship and updates from FDA, MHRA, ArrePath, ABT, Unnatural, Thryv and more
Read More
BioCentury
|
Jul 16, 2024
Management Tracks
More moves at the top for I-Mab
Plus: Daniel Janse named CEO at AffyImmune, and updates from HanAll, Mogrify, Rectify and Atsena
Read More
BioCentury
|
Apr 5, 2024
Finance
1Q24 wrap: Red rising
Winners, losers in biotech stock tiers in 1Q24
Read More
BioCentury
|
Feb 14, 2024
Product Development
Clinical report: Data from Gilead, KalVista, Takeda, Synlogic and AN2
What Gilead’s CD47 failure means for the class; KalVista to submit HAE program; Takeda advances narcolepsy therapy; and more
Read More
BioCentury
|
Sep 8, 2023
Data Byte
Follow-on financing activity dips in August
The end of summer slowed biotech follow-on activity, but the companies that did raise money have had relatively strong market performances
Read More
BioCentury
|
Sep 9, 2022
Finance
After quiet season for IPOs, Third Harmonic set to test investor appetite
The three-year-old biotech, advancing a c-Kit inhibitor to treat hives, could be the first to raise at least $150M in a NASDAQ IPO since April
Read More
BioCentury
|
Mar 25, 2022
Finance
Finding crack in IPO window, AN2 prices at parity with last private round
No step-up for single-asset AN2 as it goes public in preparation for pivotal study in lung disease
Read More
BioCentury
|
Jan 8, 2022
Deals
Jan. 7 Quick Takes: AZ adds another amyloidosis mAb via Neurimmune deal
Plus: a16z’s $9B in new funds earmarks cash for bio, and updates from Virtue, AN2, Ultragenx-Regeneron and more
Read More
BioCentury
|
Nov 21, 2019
Company News
Brii continues to grow infectious disease pipeline via deal with start-up AN2
Read More
Items per page:
10
1 - 9 of 9